Drug Profile

LY 03017

Alternative Names: LPM-526000133; LPM526000133 Fumarate; LY-03017

Latest Information Update: 31 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Luye Pharma Group
Class Antipsychotics; Fumarates
Mechanism of Action 5-HT2C serotonin receptor antagonists; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Schizophrenia

Most Recent Events

24 Nov 2025 Adverse event, pharmacokinetic and efficacy data from a preclinical studies in Alzheimer's disease, Parkinson's disease and schizophrenia released by Luye Pharma
24 Nov 2025 The US FDA approves IND application for LY 03017
28 Aug 2025 Luye Pharma announces intention to approve IND application by the US FDA in the third quarter of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com